Navigation Links
Microfluidics International Corporation Announces Second Quarter 2009 Financial Results

NEWTON, Mass., Aug. 11 /PRNewswire-FirstCall/ -- Microfluidics International Corporation (OTC Bulletin Board: MFLU), today reported unaudited financial results for the quarter ended June 30, 2009.

(Logo: )

Second quarter accomplishments:

  • Achieved positive earnings before interest, taxes, depreciation and amortization (EBITDA) of $48,000
  • Delivered strong bookings of $6.6 million with a backlog of $4.3 million at the end of the quarter primarily due to increased demand by vaccine developers
  • Entered into an R&D agreement and equipment sales order for the Company's proprietary Microfluidics Reaction Technology (MRT) with a major pharmaceutical customer
  • Entered into an exclusive distributorship agreement with Japanese-based POWREX to market, sell and service Microfluidizer(R) high shear fluid processors in the pharmaceutical, biotechnology and energy industries throughout Japan
  • Formed a strategic alliance with U.S.-based Particle Sciences to help biopharmaceutical companies leverage the most advanced and reliable nanotechnology and formulation methods available to develop, analyze and commercialize Active Pharmaceutical Ingredients (APIs)

"I believe that the generation of positive EBITDA in the midst of an extremely challenging global economy speaks to the strength of demand for our products and process consulting services as well as to the Company's long-term potential," said Michael C. Ferrara, President and Chief Executive Officer of Microfluidics. "Achieving positive EBITDA in the second quarter is an important step towards sustainable growth, generating working capital and achieving future profitability. We will continue to innovate with new products, improve international representatives and distributor coverage, streamline costs and improve quality in support of our valued customers as we strive to carry our momentum through the second half of 2009 and into next year."

"In direct support of our profitability goals, Microfluidics has strategically invested in necessary infrastructure while aggressively managing manufacturing and operating costs and quality to improve efficiency and reduce execution risk," said Peter Byczko, Vice President of Finance and Chief Accounting Officer. "We will monitor our cost structure on an ongoing basis while also preparing the Company for future growth with the introduction of three new products in the fourth quarter of 2009 and the first quarter of 2010."

Second Quarter Financial Results:

Revenues for the three months ended June 30, 2009 were $3.5 million, a decline of $900,000, or 21%, as compared to revenues of $4.4 million for the three months ended June 30, 2008. North American revenues increased 8% to $1.5 million, offset by a 35% decrease in foreign sales from $2.9 million to $1.9 million. The second quarter of 2008 had an abnormally high number of production machines sold in Europe to the pharmaceutical industry. Net loss, as measured under U.S. generally accepted accounting principles ("GAAP"), was $177,000, or $0.02 per diluted share, for the three months ended June 30, 2009 as compared to $790,000 net loss, or $0.08 per diluted share, for the same period in 2008.

EBITDA income was $48,000 for the three months ended June 30, 2009 compared with $756,000 EBITDA loss for the same period in 2008. EBITDA is a Non-GAAP financial measure. A reconciliation of GAAP net income to Non-GAAP EBITDA is provided in the financial tables that accompany this release and is discussed under the section below titled "Non-GAAP Financial Measures."

Year to Date Financial Results:

Revenues for the six months ended June 30, 2009 were $7.0 million, a decrease of $900,000, or 11%, as compared to revenues of $7.9 million for the six months ended June 30, 2008. Net loss, as measured under U.S. generally accepted accounting principles ("GAAP"), was $867,000, or $0.08 per diluted share, for the six months ended June 30, 2009 as compared to $1.2 million net loss, or $0.12 per diluted share, for the same period in 2008.

EBITDA loss was $420,000 for the six months ended June 30, 2009 compared with $1.2 million EBITDA loss for the same period in 2008.

Live Webcast:

Microfluidics International Corporation will host a webcast on Tuesday, August 11, 2009 at 8:30 a.m. Eastern Time. Participants are invited to attend the call by visiting and clicking on the webcast link in the Investors, Events section or by dialing 866-314-4483 (within the United States) or 617-213-8049 (outside the United States). The passcode for participants is 61872202.

A replay will be available approximately two hours after the live call through August 18, 2009. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 95302005. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.

About Microfluidics International Corporation

Microfluidics International Corporation designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics and inkjet ink industries. The Company applies its 20 plus years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.

Microfluidics is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to the Company's equipment customers.

Non-GAAP Financial Measures:

In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure, including EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization. Management believes these measures are useful and relevant to management for operational planning and decision making purposes, and informative to investors in their analysis of the Company's underlying business and operating performance. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.

Safe Harbor for Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Quarterly Report on Form 10-Q for the quarter ended March 31, 2009 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.

--Financial Charts to Follow--

                      Condensed Consolidated Balance Sheets
          (Unaudited - in thousands, except share and per share amounts)

                                                 June 30,        December 31,
                                                   2009              2008
                                                   ----              ----
    Current assets:
      Cash and cash equivalents                    $402           $1,895
      Accounts receivable, net of allowance
       of $44 both at June 30, 2009 and
       December 31, 2008, respectively            2,788            2,181
      Inventories                                 2,843            2,723
      Prepaid and other current assets              285              320
                                                    ---              ---
        Total current assets                      6,318            7,119
    Property and equipment, net                   1,034            1,121
    Other non-current assets                        464              480
                                                    ---              ---
        Total assets                             $7,816           $8,720
                                                 ======           ======

    Current liabilities:
      Accounts payable                           $1,151             $986
      Accrued expenses                              938            1,233
      Customer advances                             409              436
                                                    ---              ---
        Total current liabilities                 2,498            2,655
    Long-term liabilities:
      Convertible debt                            4,652            4,625
                                                  -----            -----
        Total liabilities                         7,150            7,280
                                                  -----            -----
    Stockholders' equity:
      Common stock; $.01 par value;
       30,000,000 and 20,000,000
       shares authorized; 10,607,228
       and 10,592,228 shares issued;
       10,371,782 and 10,356,782 shares
       outstanding as of June 30, 2009
       and December 31, 2008, respectively          106              106
      Additional paid-in capital                 18,135           18,042
      Accumulated deficit                       (16,906)         (16,039)
      Treasury stock, 235,446 shares,
       at cost, as of June 30, 2009
       and December 31, 2008                       (669)            (669)
                                                   ----             ----
        Total stockholders' equity                  666            1,440
                                                    ---            -----
        Total liabilities and
         stockholders' equity                    $7,816           $8,720
                                                 ======           ======

                   Condensed Consolidated Statements of Operations
            (Unaudited - in thousands, except share and per share amounts)

                          For The Three Months Ended  For The Six Months Ended
                                     June 30,                June 30,
                                     --------                --------
                                 2009        2008        2009        2008
                                 ----        ----        ----        ----

    Revenues                   $3,469      $4,374      $7,028      $7,896
    Cost of sales               1,493       2,225       3,146       3,834
                                -----       -----       -----       -----
    Gross profit                1,976       2,149       3,882       4,062
                                -----       -----       -----       -----
    Operating expenses:
      Research and
       development                393         572         845       1,062
      Selling                     913       1,196       2,129       2,128
      General and
       administrative             722       1,175       1,526       2,118
                                  ---       -----       -----       -----
    Total operating expenses    2,028       2,943       4,500       5,308
                                -----       -----       -----       -----
    Loss from operations          (52)       (794)       (618)     (1,246)
    Interest expense             (126)         (6)       (252)        (10)
    Interest income                 1          10           3          21
                                    -          --           -          --
    Net loss                    $(177)      $(790)      $(867)    $(1,235)
                                =====       =====       =====     =======
    Net loss per common share:
      Basic                    $(0.02)     $(0.08)     $(0.08)     $(0.12)
      Diluted                  $(0.02)     $(0.08)     $(0.08)     $(0.12)
        Weighted average
         number of common and
         common equivalent
         shares outstanding:
      Basic                10,371,782  10,267,981  10,371,205  10,267,981
      Diluted              10,371,782  10,267,981  10,371,205  10,267,981

               U.S. GAAP to Non-GAAP Measure Reconciliations and
     Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)
              (In thousands, except share and per share amounts)

                                For The Three Months      For The Six Months
                                   Ended June 30,            Ended June 30,
                                 -----------------         -----------------
                                 2009         2008         2009         2008
                                 ----         ----         ----         ----

    Net loss                    $(177)       $(790)       $(867)     $(1,235)

    Net interest expense
     (income)                     126           (6)         252          (10)
    Depreciation and
     amortization                  99           40          195           81
                                   --           --          ---           --
     Measure)                     $48        $(756)       $(420)     $(1,164)
                                  ===        =====        =====      =======

    Weighted average number
     of common and common
     equivalent shares

    Basic:                 10,371,782   10,267,981   10,371,205   10,267,981
    Diluted:               10,371,782   10,267,981   10,371,205   10,267,981

    EBITDA per common
     share (Non-GAAP Measure):
    Basic:                      $0.00       $(0.07)      $(0.04)      $(0.11)
    Diluted:                    $0.00       $(0.07)      $(0.04)      $(0.11)

SOURCE Microfluidics International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
2. GEN Reports on Growing Reliance on Microfluidics Technology
3. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
4. Nanopoint Applies CE Mark to Its cellTRAY(R) Imaging and Microfluidics Systems
5. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
6. Microfluidics International Corporation to Report Second Quarter 2009 Financial Results on August 11, 2009
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. The Government of Quebec and the New Canadian Government Invest in the Creation of an International Biobank
9. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
10. Arrow International Files and Mails Definitive Proxy Materials
11. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
Post Your Comments:
(Date:10/8/2015)... 2015 Global Biologics and ... and Biosimilars industry . --> Big ... Biosimilars Industry 2015 Deep Market Research Report, Size, ... professional and depth research report on Global ... ) , --> ) , ...
(Date:10/8/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, today announced its schedule of ... in the month of October: Stem Cell ... will be presenting at the annual Partnering Forum, part ... be held October 7-9 in La Jolla, ...
(Date:10/8/2015)... ... October 08, 2015 , ... ... an exclusive license agreement to develop and commercialize intellectual property rights belonging to ... agreement from February 2009, and affords exclusive worldwide rights to intellectual property based ...
(Date:10/7/2015)... ... October 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal ... October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is ... , He is the Co-Founder and Chief Science Officer of the ...
Breaking Biology Technology:
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that ... units at an issue price of US $1.20 for gross ... one common share and one half common share purchase warrant. Each whole ... until March 10, 2015 . , ...
... March 10 Bone Biologics, Inc. announced today ... shares from the Musculoskeletal Transplant Foundation (MTF). MTF now ... financing, MTF also provided a line of credit to ... by MTF that have allowed Bone Biologics, Inc. to ...
... ... ... ... ...
Cached Biology Technology:
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
(Date:9/28/2015)... JOSE, Calif. , Sept. 28, 2015 ... of human interface solutions, today announced that Lenovo has ... touch fingerprint sensor, FS4202, for its latest smartphone, the ... secure, password-free access to unlock the device and provide ... The feature-rich Natural ID FS4202 sensor ...
(Date:9/10/2015)... This report provides detailed descriptions of the sensor types ... types that will dominate in the future. Many product ... technology hype curve in the last five years before ... all of them is the prominence of sensor options ... Sensors collect data about the physical and chemical properties ...
Breaking Biology News(10 mins):
... Society today commends President Obama,s decision to sign a ... scientific evidence is used in the development of solutions ... memorandum rightly places science at the forefront of informing ... of solutions to issues such as enhancing energy security, ...
... of proteins, the molecular machines that drive all life, also ... study, in the journal Structure , reveals that after ... of innovation. The active regions of many proteins, called domains, ... host of structures that had never been seen before. This ...
... to treat critical limb ischemia in peripheral arterial ... thwarted by restenosis (the re-narrowing of the artery ... need for repeat treatments and the continued progression ... and amputation. Interventional radiologists have been studying a ...
Cached Biology News:
ma. plate stack height 70mm...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
CQCS kit for etra KR 4i , (other units)....
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
Biology Products: